Icaridin
CAS 119515-38-7
Icaridin (CAS 119515-38-7) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Icaridin used for in pharmaceutical contexts?
Icaridin (CAS 119515-38-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Icaridin?
No adverse-event association or SIDER side-effect rows are rendered for Icaridin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Icaridin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Hydroxyethyl Isobutyl Piperidine Carboxylate (Icaridin/Picaridin) with EU status "permitted".
What clinical phase is Icaridin in?
Icaridin is rendered with ChEMBL max phase 2.